EWS CENTER
ONTACT US
VEGOMEGA BIOPHARMA CO., LTD.
Email:vegomega@163.com
TEL:+86-27-86698696
Mobil:+86-18062559421
18062016861
Skype:bioomega20
WeChat:18062016861
-
2017-09-20
Congratulations to industrized technology of Palmitoleic acid
A Research Comparative of Fatty Acids – EPA and Palmitoleic Acid Palmitoleic Acid (PA) Outperforms EPA in Identical KK-Aʸ Mouse Study Regarding Effects on Triglyceride Levels and Weight Gain Research on Palmitoleic acid sponsored by Nippon Suisan Kaisha at the Central Research Laboratory in Japan¹ as compared to identical research model published through a joint collaboration of research scientists at the Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan and the Department of Nephrology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China². Background: EPA – Eicosapentaenoic acid (EPA) has been reported to have beneficial effects on the progression of various renal diseases including diabetic nephropathy; however, the precise mechanisms are not completely understood. The joint collaboration examined the effects of EPA on the early stage of type 2 diabetic nephropathy in KK-Aʸ mice and the possible role of inflammation, oxidative stress, and growth factor in this process. PA – Palmitoleic Acid Studies have demonstrated the beneficial effect of palmitoleic acid (C16:1 n-7) on reducing muscle insulin resistance and preventing beta-cell apoptosis. However, the effect of palmitoleic acid on diabetes remains to be elucidated. The aim of this study was to examine the antidiabetic effect of palmitoleic acid in KK-Aʸ mice, a spontaneous model for studies of obese type 2 diabetes with low insulin sensitivity. Methods: EPA – The treatment group was injected with EPA ethyl ester (Epadel from Mochida) at 1 g/kg per day intraperitoneally from 12 to 20 weeks of age and the control group was injected with saline. Renal morphologic examinations were performed after 8 weeks of treatment. PA – KK-Aʸ mice were orally administered 300 mg/kg of palmitoleic acid or 300 mg/kg of palmitic acid (C16:0) on a daily basis for 4 weeks and compared vs. control. Results: After 8 weeks, the EPA dosage of 45 mg daily reduced TG levels in the mice by approximately 44%, while after just 4 weeks the Palmitoleic Acid dosage of 9 mg daily reduced TG levels by approximately 50%. Additionally, the mice administered with palmitoleic acid showed a reduction in body weight increase while those administered with EPA showed no impact on body weight increase. TG levels are expressed in the chart below in mg/dL. Conclusions & Implications: At five fold less dosage, in identical animal models, with the same power estimates statistically (similar N’s = 8 & 10 animals tested) Palmitoleic Acid demonstrates very similar to superior effects to those of EPA. Therefore, the data supports that C16:1 ethyl ester is of greater potency than EPA on TG and insulin-like effects in identical mouse animal models.
-
2017-09-20
Congratulations to our company, 6 people through the civil air defense engineer practicing registration 2
111 according to the "State Council on establishing administrative license necessary administrative examination and approval of projects" (State Council Decree No. 412nd) issued by the national civil air defense office and the "air defense engineering design administrative license qualification management approach" (national defense 2013 No. 417), "the civil air defense engineering supervision administrative license management measures" (in the civil air defense 2013 No. 227), "people's air defense equipment production and installation management procedures" (national defense 2014 No. 438), the review of qualified 180 reporting units to be publicity, publicity period of 10 working days. Specific publicity follows April 19, 2013, China biotech Association gene therapy in the first branch of the members of the conference and the establishment of the General Assembly held in beijing. Gene therapy is a branch branch was formally established by the approval of the State Ministry of health, the Ministry of civil affairs, to scientific research institutions throughout the country, colleges, hospitals, biomedical experts and enterprise managers more than 50 people attended the inaugural meeting held in Beijing railway. First of all, the election conference and the first meeting of all members were held. The meeting was presided over by Wen Yong, director of the Chinese medical biotechnology association. According to the "State Council on establishing administrative license necessary administrative examination and approval of projects" (State Council Decree No. 412nd) issued by the national civil air defense office and the "air defense engineering design administrative license qualification management approach" (national defense 2013 No. 417), "the civil air defense engineering supervision administrative license management measures" (in the civil air defense 2013 No. 227), "people's air defense equipment production and installation management procedures". According to the "State Council on establishing administrative license necessary administrative examination and approval of projects" (State Council Decree No. 412nd) issued by the national civil air defense office and the "air defense engineering design administrative license qualification management approach" (national defense 2013 No. 417), "the civil air defense engineering supervision administrative license management measures" (in the civil air defense 2013 No. 227), "people's air defense equipment production and installation management procedures" (national defense 2014 No. 438), the review of qualified 180 reporting units to be publicity, publicity period of 10 working days.
-
2017-09-20
Zhao Jincheng, vice minister and professor of Nanchang University, came to our company
111 according to the "State Council on establishing administrative license necessary administrative examination and approval of projects" (State Council Decree No. 412nd) issued by the national civil air defense office and the "air defense engineering design administrative license qualification management approach" (national defense 2013 No. 417), "the civil air defense engineering supervision administrative license management measures" (in the civil air defense 2013 No. 227), "people's air defense equipment production and installation management procedures" (national defense 2014 No. 438), the review of qualified 180 reporting units to be publicity, publicity period of 10 working days. Specific publicity follows April 19, 2013, China biotech Association gene therapy in the first branch of the members of the conference and the establishment of the General Assembly held in beijing. Gene therapy is a branch branch was formally established by the approval of the State Ministry of health, the Ministry of civil affairs, to scientific research institutions throughout the country, colleges, hospitals, biomedical experts and enterprise managers more than 50 people attended the inaugural meeting held in Beijing railway. First of all, the election conference and the first meeting of all members were held. The meeting was presided over by Wen Yong, director of the Chinese medical biotechnology association. According to the "State Council on establishing administrative license necessary administrative examination and approval of projects" (State Council Decree No. 412nd) issued by the national civil air defense office and the "air defense engineering design administrative license qualification management approach" (national defense 2013 No. 417), "the civil air defense engineering supervision administrative license management measures" (in the civil air defense 2013 No. 227), "people's air defense equipment production and installation management procedures". According to the "State Council on establishing administrative license necessary administrative examination and approval of projects" (State Council Decree No. 412nd) issued by the national civil air defense office and the "air defense engineering design administrative license qualification management approach" (national defense 2013 No. 417), "the civil air defense engineering supervision administrative license management measures" (in the civil air defense 2013 No. 227), "people's air defense equipment production and installation management procedures" (national defense 2014 No. 438), the review of qualified 180 reporting units to be publicity, publicity period of 10 working days.